Atom | Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)

Funder: National Institutes of Health

Funding Amounts: No budget limit; project period up to 2 years (UG3) + up to 3 years (UH3), max 5 years total.

Summary: Supports milestone-driven, combined Phase 1/2a clinical trials of novel drugs (excluding amyloid/tau targets) for Alzheimer's disease and related dementias.

Key Information: Applications must bundle both UG3 (Phase 1) and UH3 (Phase 2a) activities and include go/no-go safety milestones; definitive efficacy (Phase 3) trials are not eligible.

Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)

Sign in to see full grant listing